AQUILO CAPITAL MANAGEMENT LLC
Q3 2021 Form 13-F
SAN FRANCISCO, CALIFORNIA
CIK 0001591986
· CRD 153022
· SEC-registered investment adviser
$550.6M Reported Value Total
AQUILO CAPITAL MANAGEMENT, LLC reports 5 total accounts under management (AUM). There are 5 discretionary accounts valued at $737,213,000, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered
Discretionary Manager
Private funds (Form ADV)
3 funds
· $277.1M gross asset value
Hedge Fund: $189.4M · Other: $87.6M
Source: Form ADV filed 2024-03-26
Reported value
$550.6M
Quarter over quarter
-3.6%
Holdings
13
Top-10 concentration
91.7%
Key People
Form ADV owners & control persons
Marc Robert Schneidman
MANAGER
Adam Scott Bristol
MANAGING DIRECTOR - HEAD OF INVESTMENTS
Tony Michael Berta
CFO AND CCO
Filing Navigation
13F Metrics
Loading 13F Metrics
Q3 2021 13F record
Q3 2021 13F filing summary
| Period of report | September 30, 2021 |
|---|---|
| Filed | November 15, 2021 |
| Form | 13F-HR |
| Reported value | $550.6M |
| Positions | 13 |
| Change in reported value | +43.1% |
| New positions | 1 |
| Exited positions | 3 |
| Position turnover | 25.0% |
| Top-10 concentration | 91.7% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q1 2025 13F
Filed May 15, 2025
|
12 | $55.8M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
13 | $66.3M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
13 | $131.9M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
13 | $103.7M |
|
Q1 2024 13F
Filed May 15, 2024
|
10 | $133.4M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
9 | $160.5M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
12 | $110.4M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
12 | $180.5M |
|
Q1 2023 13F
Filed May 15, 2023
|
11 | $241.3M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
12 | $266.2M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
14 | $277.4M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
12 | $293.0M |
|
Q1 2022 13F
Filed May 16, 2022
|
12 | $680.4M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
13 | $881.7M |
|
Q3 2021 13F
Filed Nov 15, 2021
|
13 | $550.6M |
|
Q2 2021 13F
Filed Aug 16, 2021
|
15 | $384.9M |
|
Q1 2021 13F
Filed May 17, 2021
|
15 | $553.4M |
|
Q4 2020 13F
Filed Feb 16, 2021
|
15 | $481.2M |
|
Q3 2020 13F
Filed Nov 16, 2020
|
15 | $944.6M |
|
Q2 2020 13F
Filed Aug 14, 2020
|
13 | $495.9M |
6 earlier quarters on file — choose one from the quarter menu above.
Top 14 holdings · Q3 2021
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | XBI P SPDR S&P BIOTECH ETF TR | $125.7M | 22.83% |
| 2 | SPRO SPERO THERAPEUTICS INC | $84.0M | 15.26% |
| 3 | BPMC BLUEPRINT MEDICINES CORP | $53.6M | 9.74% |
| 4 | DRNA DICERNA PHARMACEUTICALS INC | $49.5M | 8.99% |
| 5 | QURE UNIQURE NV | $42.2M | 7.67% |
| 6 | RGNX REGENXBIO INC | $35.2M | 6.39% |
| 7 | ARWR ARROWHEAD PHARMACEUTICALS INC | $33.0M | 5.99% |
| 8 | FDMT 4D MOLECULAR THERAPEUTICS INC | $29.7M | 5.39% |
| 9 | ARVN ARVINAS INC | $29.2M | 5.29% |
| 10 | DNTH MAGENTA THERAPEUTICS INC | $23.0M | 4.17% |
| 11 | AMYT AMRYT PHARMA PLC | $16.7M | 3.04% |
| 12 | PIRS PIERIS PHARMACEUTICALS INC | $16.5M | 3.0% |
| 13 | ARGX ARGENX SE | $6.7M | 1.22% |
| 14 | GMAB GENMAB A/S | $5.6M | 1.01% |
Values as reported on the Q3 2021 Form 13F. Every position is in the holdings table below.